$AXON

Kalinowski Caitlin Elizabeth sold $38K of AXON

Kalinowski Caitlin Elizabeth sold 80 shares of AXON ENTERPRISE, INC. (AXON) at $477.38 on 2026-06-01.

Original reporting
SEC EDGAR · Kalinowski Caitlin Elizabeth
Published Jun 2, 2026, 9:23 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 2, 2026, 9:24 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$AXON
Neutral
high confidence
Mentioned
$AXON
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AXONNeutralLow
01

Why it matters

This provides incremental ownership-flow information but no new company performance or guidance data.

02

Market read

Traders may monitor for patterns in insider activity, but this specific filing alone is unlikely to drive a material repricing.

03

What to watch

The filing notes no pre-arranged 10b5-1 plan; however, without additional context or follow-on transactions, it remains low-signal.

Relevance 6/10Novelty 6/10Timing: After-hours/filing update (SEC Form 4 filed June 2, covering June 1 sale)

Background

The article is an SEC EDGAR Form 4 insider transaction disclosure for AXON, reporting a director’s open-market sale.

Company-level read

Ticker impact

$AXONNeutralHigh confidence
Context

Director Kalinowski sold 80 AXON shares in an open-market transaction disclosed via SEC Form 4 on June 1, 2026.

Expected impact

Likely limited near-term impact; treat as low-signal unless repeated or paired with other negative disclosures.

Evidence & confidence

This is a routine Form 4 sale with no stated reason, no 10b5-1 plan, and no accompanying company-specific news (earnings, guidance, deals, litigation).

Market effects

Minimal—single-company insider transaction without sector-wide signal.

None indicated.

None indicated.

Counterpoint

The sale could be unrelated to fundamentals (tax/portfolio rebalancing), so overreacting may be unwarranted.

Key entities

  • AXON ENTERPRISE, INC.

    Issuer of the securities subject to the Form 4 insider sale.

  • Caitlin Elizabeth Kalinowski

    Director who sold 80 shares of AXON on June 1, 2026.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$AXONMedAI 8/10

Axon’s AI Era Revenue Jumped Nearly 700%. Here’s What’s Behind It

Axon Enterprise (AXON) reported 35% revenue growth to $904M, beating estimates. AI Era revenue surged nearly 700% YoY. Management raised full-year guidance to 32-34% growth. Gross margin slipped 40 basis points to 62.9%. Analysts estimate a target price of $714, implying 13.7% upside over 2.4 years. The stock trades at 70x forward earnings, with growth driven by software and AI products.

$BABAHighAI 8/10

Breakfast News: Alibaba's AI Push Comes at a Cost

Alibaba's Q1 revenue rose 9% to $39.6B, but operating income fell 57% due to tech investments. BILL Holdings reported 14% revenue growth and 80% operating income increase. U.S. debt surpassed $40T, with Treasury buybacks easing yield pressure. Apple plans 2027 launch for camera AirPods. Axon Enterprise passes competitive position tests, with a 69% potential upside to $1,088.08.

$AXONMed

Axon Stock Rebounds As Its Margin Squeeze Looks Like The Price Of Growth

Axon Enterprise (AXON) shares rose 9.3% on Friday after a 14.3% drop the prior session following its Q2 2026 results. The quarter showed revenue of $904 million, up 35% year over year, and a raised full-year outlook. The market disagreed over margin compression tied to higher memory costs and counter-drone hardware mix, with Axon expecting Q3 adjusted EBITDA margin to hold and rebuild in Q4.

$AXONMed

Raise. So Why Is the Stock Down?

Axon Enterprise (NASDAQ: AXON) reported Q2 revenue of $904M, up 35% year over year, beating estimates of $876.5M. Adjusted EBITDA rose 40% to $242M, and adjusted EPS was $1.88 vs $1.84 expected. Axon raised full-year revenue guidance to 32%-34% growth but reduced software and services gross margin and withdrew operating cash flow and free cash flow guidance.